Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00026208 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | completed | Phase 2 | 76 | Stanford UniversityOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity(BREVITY) | completed | Phase 2 | 38 | University of BirminghamOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00385788 | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT01393717 | Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma | completed | Phase 2 | 57 | City of Hope Medical CenterOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT01534078 | Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01969435 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT02244021 | BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV | completed | Phase 2 | 13 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT02247869 | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | completed | Phase 2 | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients(HD0801) | completed | Phase 2 / Phase 3 | 520 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00667615 | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00540007 | Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 80 | Washington University School of MedicineOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00388349 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | completed | Phase 2 | 146 | Stanford UniversityOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00003820 | Rituximab in Treating Patients With Hodgkin's Lymphoma | completed | Phase 2 | 39 | Ranjana AdvaniOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00848926 | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 5 | Mar 13, 2017 | clinicaltrials |
| NCT00733824 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00705250 | Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | completed | Phase 2 | 110 | Seagen Inc.INDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00683046 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 2 | 204 | University of ChicagoOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT01523847 | A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)(HD0803) | completed | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 4, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01195766 | Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | completed | Phase 2 | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00163748 | Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma | completed | Phase 2 | 40 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00163761 | Efficacy Study of Outpatient Therapy for Lymphoma | completed | Phase 2 | 90 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00592111 | A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) | completed | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00001575 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | completed | Phase 1 / Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00082966 | Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT01164345 | Mozobil for Autologous Stem Cell Mobilization | completed | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01187303 | Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) | completed | Phase 2 | 28 | University of CologneOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00284804 | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | completed | Phase 2 | 74 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2018source: clinicaltrials